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Abstract
Background: The incidence of Gestational Diabetes Mellitus (GDM) is rising in all developed countries. This study
aimed at assessing the short-term economic burden of GDM from the Italian healthcare system perspective.
Methods: A model was built over the last pregnancy trimester (i.e., from the 28th gestational week until childbirth
included). The National Hospital Discharge Database (2014) was accessed to estimate delivery outcome probabilities
and inpatient costs in GDM and normal pregnancies (i.e., euglycemia). International Classification of Disease-9th
Revision-Clinical Modification (ICD9-CM) diagnostic codes and Diagnosis-Related Group (DRG) codes were used to
identify GDM cases and different types of delivery (i.e., vaginal or cesarean) within the database. Neonatal outcomes
probabilities were estimated from the literature and included macrosomia, hypoglycemia, hyperbilirubinemia, shoulder
dystocia, respiratory distress, and brachial plexus injury. Additional data sources such as regional documents, official
price and tariff lists, national statistics and expert opinion were used to populate the model. The average cost per case
was calculated at national level to estimate the annual economic burden of GDM. One-way sensitivity analyses and
Monte Carlo simulations were performed to quantify the uncertainty around base case results.
Results: The amount of pregnancies complicated by GDM in Italy was assessed at 54,783 in 2014 using a prevalence
rate of 10.9%. The antenatal outpatient cost per case was estimated at €43.7 in normal pregnancies compared to €370.
6 in GDM patients, which is equivalent to a weighted sum of insulin- (14%; €1034.6) and diet- (86%; €262.5) treated
women’s costs. Inpatient delivery costs were assessed at €1601.6 and €1150.3 for euglycemic women and their infants,
and at €1835.0 and €1407.7 for GDM women and their infants, respectively. Thus, the overall cost per case difference
between GDM and normal pregnancies was equal to €817.8 (+ 29.2%), resulting in an economic burden of about €44.8
million in 2014 at national level. Probabilistic sensitivity analysis yielded a cost per case difference ranging between
€464.9 and €1164.8 in 80% of simulations.
Conclusions: The economic burden of GDM in Italy is substantial even accounting for short-term medical costs only.
Future research also addressing long-term consequences from a broader societal perspective is recommended.
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Background
Gestational Diabetes Mellitus (GDM) is defined as “any
degree of glucose intolerance with onset or first recogni-
tion during pregnancy” and represents one of the most
common complications [1]. GDM is associated with
higher risk for adverse pregnancy outcomes as well as an
increased probability of developing future type 2
diabetes mellitus in both mother and infant [2–5].
In Italy, a 75-gr oral glucose tolerance test (OGTT) for
GDM is recommended at weeks 16–18 and/or at week
24–28 of pregnancy according to pre-defined risk factors
including age, body mass index (BMI), family history of
type 2 diabetes, previous history of GDM, and ethnicity
[6]. According to the criteria promoted by the Inter-
national Association of Diabetes and Pregnancy Study
Groups (IADPSG) in 2010 [7], GDM prevalence was
recently assessed at around 11% in Italy [8, 9]. This rate
is 25% higher than the value estimated ten years before
with the old criteria and may affect both the pre- and
post-natal healthcare burden in the near future [8–12].
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The prevalence rate is aligned with data from other
countries, where GDM is estimated to affect between 1%
and 15% of pregnancies depending on ethnicity and
diagnostic criteria adopted [12]. The aim of this study
was to estimate the economic burden of GDM over the
last pregnancy tem in Italy compared to normal preg-
nancies (i.e., euglycemia) from a national healthcare
system perspective.
Methods
A model covering a period of three months (around
90 days) ranging from the 28th gestational week until
childbirth (included) was built in Microsoft Excel (2013)
and Tree Age Pro (2015).
Data sources
Data from the Italian National Hospital Discharge
Database (HDD) provided by the Ministry of Health
were accessed in order to obtain information about the
women’s characteristics and types of childbirth in GDM
and normal pregnancies [13]. The database covers all
hospitalizations in any public or private healthcare
facility in any part of Italy. Women who gave birth were
identified through specific Diagnosis-Related Group
(DRG) codes (370–375) for birth or using International
Classification of Disease-9th Revision-Clinical Modifica-
tion (ICD9-CM) diagnostic codes that indicated child-
birth (details are available on request) where resulting
DRG codes were outside the expected range (e.g., for se-
vere complications requiring surgery). GDM cases were
discerned in the HDD using the ICD9-CM code 648.8,
either in the birth admission or through linking the
identification (ID) number of the mother to admissions
during a three-month period prior to delivery. DRG
codes (370–375) were used to discriminate among the
different delivery methods and calculate the correspond-
ing probabilities and costs in GDM and euglycemia (ex-
cluding those admissions for childbirth with other DRG
codes). A separate database of the infants’ hospitaliza-
tions for birth was extracted, which was used to estimate
the average hospitalization costs of infants affected by
neonatal complications frequently associated with GDM
as compared to a normal newborn’s cost.
Probabilities of GDM-related neonatal outcomes were
obtained from the literature since it was not possible to
identify children born to GDM mothers. In HDD, about
one third of the newborns lack a unique ID code (i.e.,
unique IDs, assigned after birth, are not always included
in the birth discharge record); the date of birth, age in
days and residence are not provided; and no code exists
to link infants with their mothers in the dataset. After a
review of the literature, we agreed to rely on a large
retrospective study of 36,241 women with and without
GDM that allowed all risk varying according to the
presence or not of macrosomia (i.e., birthweight ≥4 kg)
[14]. Indeed, GDM is an established risk factor for
macrosomia, which is in turn associated with several ad-
verse neonatal outcomes [2]. The probability of giving
birth to a normal infant was obtained by difference in
the model. The number of births in 2014 (502,596) as
reported by official statistics [15] was used as a ‘proxy’ of
the number of pregnant women in the same period, al-
though their number might be slightly different due to
multiple pregnancies and stillbirths.
Cost analysis
The cost analysis was conducted from the perspective of
the Italian National Health Service. Italy has a tax-based
system funded mainly through reimbursement tariffs
using DRGs for hospital care and national/regional tar-
iffs for outpatient services and materials (with some use
of additional subsidies from individual regions to their
hospitals and patient co-payments for medications and
outpatient services). In this study, antenatal outpatient
and inpatient delivery costs broken down between
mother and infant were calculated in GDM and euglyce-
mia, respectively; DRG tariffs were used as a ‘proxy’ for
inpatient costs. No discounting was applied as the time
horizon was shorter than one year.
Mothers’ delivery costs were calculated as DRG tariffs
adjusted for the length of stay (LOS). In detail, a cost
per admission day was obtained for each delivery
method by dividing the official tariff by the average LOS
in days across all women in labor identified in the HDD.
Then, the daily cost was multiplied by the average LOS
in GDM and euglycemic women, respectively, in order
to obtain the average cost of a delivery stay in the two
women’s groups. In this cost calculation, we excluded
‘outliers’ defined as admissions with a LOS above the 99°
percentile in the HDD.
From the infant’s perspective, no cost values were
assigned to macrosomia as such, but only to the
events that followed; we calculated the average cost
of admissions reporting each complication considered
in the model adjusted for the LOS. For example, the
cost associated with respiratory distress represented
the average reimbursement tariff of all admissions
reporting ICD9-CM diagnostic code 769 (neonatal re-
spiratory distress) in the HDD 2014. In the model,
the cost of a normal childbirth was assessed at €560
(DRG 391).
An average cost per case was obtained in GDM and
euglycemia, respectively, as the sum of the products of
probabilities and costs attached to each maternal and
neonatal event considered in the model. Therefore, the
annual economic burden of GDM in Italy for the year
2014 was estimated by multiplying the number of GDM
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cases (using a prevalence rate of 10.9% [8]) by the differ-
ence in cost per case between GDM and euglycemia [2].
Sensitivity analyses
We conducted both deterministic and probabilistic sen-
sitivity analyses in order to test the robustness of base
case results. One-way sensitivity analyses were applied
by varying (± 20%) the probabilities retrieved from the
literature (i.e., infant complications) and all inpatient
costs in the model. In probabilistic sensitivity analysis
(i.e., Monte Carlo simulations), probabilities were mod-
eled using a beta distribution and costs using a gamma
distribution.
Results
Mother’s characteristics
After exclusions for lack of a unique (blinded) ID
(44,402, 9.1%) and accounting for multiple pregnancies
in one year (122), the characteristics of the 445,812 preg-
nant women uniquely identified in the database and de-
livering in 2014 were preliminarily investigated and
presented in Table 1. Women with a GDM diagnosis
were more likely to be in advanced maternal age, over-
weight - BMI ≥25 Kg/m2 and/or obese - BMI ≥30 Kg/m2
(ICD9-CM: 649.1; 278.0), have a nationality other than
Italian and a lower educational level compared to eugly-
cemic ones.
Antenatal outpatient costs
The screening and treatment path for GDM, as recom-
mended by Italian guidelines, is reported in Fig. 1 [6]. In
this study, we assumed all GDM diagnoses occurred at
the 28th week of gestation. Accordingly, Table 2 summa-
rizes resources consumption and costs associated with
the different blood glucose states during the last preg-
nancy trimester. Insulin-treated GDM patients (14%)
[16] perform a blood glucose test four times a day (i.e.,
fasting, and 1 h after breakfast, lunch, and dinner) with
a portable glucometer, while those under a special diet
and exercise regimen only can limit testing to two sur-
veys per day [10, 17]. In case of variable consumption
frequencies (e.g., once or twice a day), the lowest bound
(e.g., once a day) was conservatively adopted to estimate
the costs. The cost of insulin therapy was assessed by re-
ferring to the most prescribed drug (i.e., insulin aspart)
for GDM in Italy. Additional visits and exams, including
a visual field test for eye complications, were reported
in GDM women during pregnancy [17]. The cost of
one oral 75-g OGTT was included to account for an
extra test prescribed to GDM women shortly after
delivery [6].
Inpatient costs
Maternal events resulting in hospitalization in the model
represented the different delivery options as described by
the DRG system (codes: 370–375); the corresponding
probabilities were retrieved from the HDD for normal
pregnancies and those complicated by GDM, respectively
(Table 3). The analysis was performed on 442,285 deliver-
ies after excluding 3650 records with other DRG codes.
The health events considered for infants were
hypoglycemia (blood glucose < 35 mg/dL), hyperbiliru-
binemia (total serum bilirubin > 5 mg/dL), respiratory
distress, shoulder dystocia and brachial plexus injury
as reported by the study from Esakoff et al. [14]; the
risk of macrosomia was retrieved instead by an Italian
study [18] (Table 4).
Inpatient costs estimated for each event considered in
the model are reported in Table 5. For neonatal compli-
cations, a unique cost value was reported since the data-
base does not allow to distinguish between children
born from GDM and euglycemic mothers.
Overall costs
As reported in Table 6, the base case analysis yielded a
cost per GDM case equal to €3613.4 divided into ante-
natal outpatient (€370.6) and inpatient costs for mother
(€1835.0) and infant (€1407.7).
GDM outpatient costs corresponded to a weighted
sum of insulin- and diet-treated women’s costs and were
on average €326.9 higher than in euglycemic women.
Similarly, total inpatient costs (mother and infant) in
GDM (€3242.8) outweighed those in normal pregnancies
(€2751.9). Overall, each pregnancy affected by GDM cost
29.2% more than a pregnancy without GDM, with a cost
per case difference of €817.8. The number of
Table 1 Mother’s characteristics by euglycemic status
GDM (N = 11,540) Euglycemia (N = 434,272) Source
Age (mean ± SD) 33.7 ± 5.4 31.6 ± 5.6 [13]
Advanced age (≥35) 5369 46.5% 140,238 32.3% [13]
Overweight/Obesity 276 2.4% 1190 0.3% [13]
Foreign citizenship 3920 34.0% 82,433 19.0% [13]
University degreea 1370 13.3% 61,349 15.1% [13]
aEducation level was reported in 416,079 of records (93.3%)
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pregnancies affected by GDM was estimated at 54,783
(out of 502,596 births) in 2014, resulting in an extra cost
of around €44.8 million for the Italian National Health
Service.
Sensitivity analyses
In Table 7 we showed the effects of varying selected
parameters on the inpatient cost per case difference
between GDM and euglycemia. The largest impact on
Δ cost/case was obtained by varying ±20% the cost of
cesarean section without complications in GDM,
which yielded an interval of the cost difference equal
to €324.1 - €657.7.
Figure 2 displays Monte Carlo probability distributions
(1000 iterations) of the expected inpatient cost per case
in euglycemic and GDM women, respectively. The pos-
sible values ranged between €2326.6 and €3206.6 in
euglycemia and €2792.0 and €3890.4 in GDM. However,
80% of the expected cost values were included in the
range €2577.7 - €2915.7 in euglycemia and €3053.7 -
€3415.6 in GDM. Under these simulations, inpatient
cost per case difference between GDM and euglycemia
might vary between €138.0 and €837.9 which, summed
with the outpatient cost/case difference (€326.9), would
give an overall cost/case difference range of €464.9 -
€1164.8.
Discussion
Main findings
There is a lack of research on the burden associated with
GDM in many countries, masking its potential import-
ance for policy-makers. To our knowledge, this is the
first study to estimate the economic consequences of
GDM in Italy.
This analysis showed that pregnant women affected by
GDM are more likely to present established risk factors
Fig. 1 Screening and treatment path for GDM. The figure shows the generic framework of GDM screening path as recommended by Italian
guidelines. The square node on the far left symbolizes the choice between the two screening options; circles represent chance events. The
symbol # indicates that probabilities of that branch are complementary to those of the parallel branch. Triangles represent the terminal nodes
Table 2 Antenatal outpatient costs by mother’s euglycemic status
Category Resource Consumption Code Unit cost (€) Total costs per case (€) Source
GDM (Diet) GDM (Insulin) Euglycemia GDM
(Diet)
GDM
(Insulin)
Euglycemia
Screening OGTT 75 g 2 2 1 90.26.4 2.38 4.76 4.76 2.38 [6]
Self-monitoring
blood glucose kit
Glucometer Yes Yes No – Free of charge 0.0 0.0 0.0 Expert opinion
Test strip 2/day 4/day No – 0.55 99.0 198.0 0.0 [10, 17, 23]
Finger stick 2/day 4/day No – 0.10 18.0 36.0 0.0 [24]
Insulin therapy Insulin (shot) No 1–2 shots/day No – 6.34 0.0 570.6 0.0 [17, 25]
Needle No No – 0.14 0.0 12.6 0.0 [24]
Syringe No No – 0.11 0.0 9.9 0.0 [24]
Visits and exams Obstetric visit Every 3–4
weeks
Every 1–2
weeks
Every 5–6
weeks
89.26 20.66 62.0 124.0 41.3 Expert opinion; [26]
Obstetric
ultrasound
2 (at 32th week
and 36th week)
No 88.78.2 30.99 62.0 62.0 0.0 Expert opinion; [17]
Visual field
test
1 No 95.05 16.78 16.8 16.8 0.0 [17]
Total costs 262.5 1034.6 43.7
Meregaglia et al. BMC Pregnancy and Childbirth  (2018) 18:58 Page 4 of 9
such as obesity, advanced maternal age, non-Italian citi-
zenship, and low educational level and to experience ad-
verse pregnancy outcomes. Even accounting for short-
term medical costs only, the yearly economic burden of
GDM was substantial (€44.8 million) in 2014. At the
outpatient level, a relevant difference in cost (+ 748%)
was observed between GDM and euglycemic women,
while in terms of hospitalization, mother and infant
costs were respectively 14.6% and 22.3% higher than in
euglycemia. These results remained robust after per-
forming both deterministic and probabilistic sensitivity
analysis.
Strengths and limitations
The main strength of this study was the availability of
administrative data on hospital discharges for all
women who delivered in 2014 in Italy. As a check on
the reliability of the data, we measured an infant
mortality rate of 3.3 per 1000 live births, which is in
line with the rate of 3.1 in published data for Italy
[15]. However, our database contained fewer women
(445,812) uniquely identified as giving births than
those reported by official statistics (502,596), likely
due to exclusions for incomplete (blinded) ID codes
and inconclusive diagnostic and DRG coding. We also
found wide, unexplained variation in the percentage
of women with a GDM diagnosis among regions
(from 0.5% in Aosta Valley to 6.1% in Tuscany) and a
low overall GDM rate (< 3%) in hospital delivery re-
cords, even though clinical studies [8, 9] and expert
opinion estimated the prevalence to be 10% or more
in Italy. This inconsistency (and presumed under-
reporting) is likely due to variation among regions in
coding practices and number of diagnostic code fields
reported at discharge, plus a lack of financial incen-
tive to consistently record secondary diagnoses. This
is a main limiting factor in using administrative data
rather than medical records for research purposes.
This analysis also presented a few additional limita-
tions. First, the costs associated to GDM were likely to
be underestimated for several reasons. For example, we
only considered the public expenditure for GDM, while
out-of-pocket expenses for extra visits and exams, nutri-
tional supplements, food substitution and physical activ-
ity may be substantial. Moreover, we did not consider
that GDM can be diagnosed at an earlier pregnancy
stage (16th–18th week) in high-risk women, nor that it
may be under diagnosed in women without any of the
risk factors required to perform the OGTT test. We also
disregarded that women can be admitted at the hospital
during the pre-delivery period for complications related
to GDM, and that patient compliance in performing
daily glucose tests or assuming the prescribed therapies
may not be perfect.
Second, the data sources for mother’s and infant’s
events were very different, since for the latter it was
not possible to derive GDM-related probabilities from
the HDD due to the unknown mother’s glycemic sta-
tus; in particular, we referred to a single study [14]
reporting perinatal outcomes in infants born in San
Francisco before 2006. Until now, no study has re-
ported all the neonatal outcomes of interest for Italy
through a comparison between GDM and non-GDM
women, thus it was not possible to refer to a more
recent and country-specific study. However, some of
the outcomes reported by the reviewed study [14]
Table 3 Delivery options probabilities by mother’s euglycemic status
DRG Description Euglycemia (N = 430,851) GDM (N = 11,434) Source
370 Caesarean section with CC 11,437 2.6% 538 4.7% [13]
371 Caesarean section without CC 145,212 33.7% 4019 35.2% [13]
372 Vaginal delivery with CC 9447 2.2% 447 3.9% [13]
373 Vaginal delivery without CC 260,036 60.3% 6287 55.0% [13]
374 Vaginal delivery with sterilization and/or dilatation and curettage 4274 1.0% 125 1.1% [13]
375 Vaginal delivery with other interventions but sterilization and/or dilatation and curettage 445 0.1% 18 0.2% [13]
Table 4 Neonatal events probabilities by mother’s euglycemic status
Macrosomia Hypoglycemia Hyperbilirubinemia Shoulder dystocia Respiratory distress Brachial plexus injury Normal newborn
Euglycemia Yes (7.4%) 2.4% 7.6% 6.0% 1.7% 0.7% 81.6%
No 1.2% 9.1% 0.9% 1.2% 0.1% 87.5%
GDM Yes (8.7%) 5.3% 13.2% 10.5% 4.0% 2.6% 64.4%
No 2.6% 10.4% 1.6% 1.5% 0.2% 83.7%
Source [18] [14] [14] [14] [14] [14] Own calculation
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were aligned with the values indicated in the Italian
literature; for example, in GDM, fetal distress was es-
timated at 3.4% and hypoglycemia at 2.5% in the
study by Lapolla et al. [18]; unfortunately, the authors
did not provide these figures for normal pregnancies.
Third, we adopted a national reference for reim-
bursement tariffs to model costs, although tariffs may
vary at the regional level in Italy. The inter-regional
unitary tariff for DRGs is the best available estimate
of hospitalization costs across regions, although it
represents an approximation of real costs; the produc-
tion cost, indeed, is only one of the variables used for
setting tariffs [19]. Thus, we performed sensitivity
analysis on inpatient costs to consider any potential
variations.
Interpretation
According to the literature, the GDM rate is growing
rapidly worldwide with a consequent large healthcare
cost increase [20]. A cluster-randomized trial from
Finland [21] reported that mean healthcare costs, in-
cluding both inpatient and outpatient care before and
after delivery, were 25% higher in women diagnosed with
GDM (€6432) than among euglycemic women (€5143)
in the 2007–2009 period. Moreover, women affected
by GDM were more likely to be in advanced maternal
age, overweight or obese and with a low educational
level.
A recent modeling study [2] conducted in the US esti-
mated a short-term cost of GDM of $1.8 billion in 2014
(corresponding to around €1.5 billion) using a preva-
lence rate of 5.5%, which might underestimate the real
GDM burden since the US did not adopt the IADSPG
criteria [22]. The average additional cost per case was
$15,593 (around €13,700).
Due to differences in methodological approaches and
healthcare financing systems, findings from previous
studies were hardly comparable with ours; however, they
confirmed a substantial economic burden of GDM at
least in developed countries. This study, unlike the
Finnish one, did not adopt an experimental design, and
relied instead on heterogeneous data sources to estimate
the costs of GDM in Italy; however, by using administra-
tive data, we could review a much larger sample of ob-
servations that those generally available in empirical
studies.
Table 5 Inpatient costs (€) of mother’s and neonatal events
Code(s) Event Cost (€) Source
Euglycemia GDM
Mother 370a Caesarean section with CC 2774.5 2938.5 [13]
371a Caesarean section without CC 2084.3 2373.0 [13]
372a Vaginal delivery with CC 1610.3 1802.8 [13]
373a Vaginal delivery without CC 1269.3 1385.2 [13]
374a Vaginal delivery with sterilization and/or dilatation and curettage 2116.0 2330.9 [13]
375a Vaginal delivery with other interventions but sterilization and/or dilatation and curettage 2842.0 3265.9 [13]
Infant 769b Respiratory distress 24,337.8 [13]
775.0/775.6b Hypoglycemia 6571.8 [13]
774.2/774.6b Hyperbilirubinemia 2854.2 [13]
767.6b Brachial plexus injury 1671.9 [13]
660.4b Shoulder dystocia 1407.6 [13]
391a Normal newborn 560.0 [13]
aDRG; bICD9-CM
Table 6 Mother’s and infant’s cost per case (€) by mother’s euglycemic status
Outpatient Inpatient Inpatient cost/case Total cost/case
Mother Mother Infant
Euglycemia 43.7 1601.6 1150.3 2751.9 2795.6
GDM 370.6 1835.0 1407.7 3242.8 3613.4
Diet (86%) 262.5 – – – –
Insulin (14%) 1034.6 – – – –
Delta 326.9 233.4 257.4 490.9 817.8
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Conclusions
This study should be interpreted as a first step towards
further research in diabetes in pregnancy and highlights
the need of collecting additional data regarding GDM in
Italy and elsewhere. Parameters included in this model
are likely to be used in future cost-effectiveness analyses
of novel GDM treatments or preventive interventions
targeted to women of childbearing age. Our analysis
Table 7 One-way sensitivity analysis on the inpatient costs per case (€)
Cost/case (euglycemia) Cost/case (GDM) Δ cost/case
Base case 2751.8 3242.7 490.9
Costs (€)
Hypoglycemia
−20% 2734.9 3205.4 470.5
+ 20% 2768.8 3280.0 511.2
Respiratory distress
− 20% 2691.6 3159.1 467.5
+ 20% 2812.1 3326.3 514.2
Cesarean section with CC (GDM)
− 20% 2751.8 3215.0 463.2
+ 20% 2751.8 3270.4 518.6
Cesarean section without CC (GDM)
− 20% 2751.8 3075.9 324.1
+ 20% 2751.8 3409.5 657.7
Vaginal delivery without CC (GDM)
− 20% 2751.8 3090.3 338.5
+ 20% 2751.8 3395.0 643.2
Cesarean section without CC (euglycemia)
− 20% 2611.4 3242.7 631.3
+ 20% 2892.3 3242.7 350.4
Vaginal delivery without CC (euglycemia)
− 20% 2598.6 3242.7 644.1
+ 20% 2905.1 3242.7 337.6
Probabilities
Hyperbilirubinemia (GDM/no macrosomia)
− 20% 2751.8 3199.1 447.3
+ 20% 2751.8 3286.3 534.5
Hypoglycemia (GDM/no macrosomia)
− 20% 2751.8 3214.2 462.4
+ 20% 2751.8 3271.2 519.4
Respiratory distress (GDM/no macrosomia)
− 20% 2751.8 3177.6 425.8
+ 20% 2751.8 3307.8 556.0
Hyperbilirubinemia (euglycemia/no macrosomia)
− 20% 2713.2 3242.7 529.5
+ 20% 2790.5 3242.7 452.2
Respiratory distress (euglycemia/no macrosomia)
− 20% 2699.0 3242.7 543.7
+ 20% 2804.7 3242.7 438.0
Meregaglia et al. BMC Pregnancy and Childbirth  (2018) 18:58 Page 7 of 9
focused on the gestational period only, but long-term
consequences of GDM in mother (i.e., type 2 diabetes)
and infant (i.e., type 2 diabetes, congenital malforma-
tions, obesity, and cardiovascular diseases) are likely to
increase the estimated economic burden. Thus, add-
itional studies investigating GDM-related effects over
mothers’ and infants’ lifetimes are also needed.
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